Charni-Natan M, Goldstein I. Protocol for Primary Mouse Hepatocyte Isolation. STAR Protoc. 2020 Sep 18;1(2):100086. doi: 10.1016/j.xpro.2020.100086. eCollection 2020 Sep 18.

Goldstein, I. Chromatin Regulation and Transcription Factor Cooperation in Liver Cells. In The Liver (eds I.M. Arias, H.J. Alter, J.L. Boyer, D.E. Cohen, D.A. Shafritz, S.S. Thorgeirsson and A.W. Wolkoff) 2020


Grøntved LGoldstein I. Editorial: Regulating Liver Transcriptional Networks by Endocrine, Extracellular, and Intrinsic Cues. Front Endocrinol (Lausanne). 2019 Dec 13;10:878.


Goldstein I, Hager GL. The Three Ds of Transcription Activation by Glucagon: Direct, Delayed, and Dynamic. Endocrinology. 2018 Jan 1;159(1):206-216. doi: 10.1210/en.2017-00521. Review. 

Goldstein I, Hager GL. Dynamic enhancer function in the chromatin context. Wiley Interdiscip Rev Syst Biol Med. 2018 Jan;10(1). doi: 10.1002/wsbm.1390. Epub 2017 May 22. Review. 



Goldstein I, Paakinaho V, Baek S, Sung MH, Hager GL. Synergistic gene expression during the acute phase response is characterized by transcription factor assisted loading. Nat Commun. 2017 Nov 29;8(1):1849. doi: 10.1038/s41467-017-02055-5.

Goldstein I, Baek S, Presman DM, Paakinaho V, Swinstead EE, Hager GL. Transcription factor assisted loading and enhancer dynamics dictate the hepatic fasting response. Genome Res. 2017 Mar;27(3):427-439. doi: 10.1101/gr.212175.116. Epub 2016 Dec 28.

Baek S, Goldstein I, Hager GL. Bivariate Genomic Footprinting Detects Changes in Transcription Factor Activity. Cell Rep. 2017 May 23;19(8):1710-1722. doi: 10.1016/j.celrep.2017.05.003. 


Isaac R, Goldstein I, Furth N, Zilber N, Streim S, Boura-Halfon S, Elhanany E, Rotter V, Oren M, Zick Y. TM7SF3, a novel p53-regulated homeostatic factor, attenuates cellular stress and the subsequent induction of the unfolded protein response. Cell Death Differ. 2017 Jan;24(1):132-143.


Swinstead EE, Miranda TB, Paakinaho V, Baek S, Goldstein I, Hawkins M, Karpova TS, Ball D, Mazza D, Lavis LD, Grimm JB, Morisaki T, Grøntved L, Presman DM, Hager GL. Steroid Receptors Reprogram FoxA1 Occupancy through Dynamic Chromatin Transitions. Cell. 2016 Apr 21;165(3):593-605.

Charni M, Molchadsky A, Goldstein I, Solomon H, Tal P, Goldfinger N, Yang P, Porat Z, Lozano G, Rotter V. Novel p53 target genes secreted by the liver are involved in non-cell-autonomous regulation. Cell Death Differ. 2016 Mar;23(3):509-20.


Goldstein I, Hager GL. Transcriptional and Chromatin Regulation during Fasting - The Genomic Era. Trends Endocrinol Metab. 2015 Dec;26(12):699-710. doi: 10.1016/j.tem.2015.09.005. Epub 2015 Oct 29. Review.


Shetzer Y, Kagan S, Koifman G, Sarig R, Kogan-Sakin I, Charni M, Kaufman T, Zapatka M, Molchadsky A, Rivlin N, Dinowitz N, Levin S, Landan G, Goldstein I, Goldfinger N, Pe'er D, Radlwimmer B, Lichter P, Rotter V, Aloni-Grinstein R. The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele. Cell Death Differ. 2014 Sep;21(9):1419-31.


Madar S*, Goldstein I*, Rotter V. 'Cancer associated fibroblasts' - more than meets the eye. Trends Mol Med. 2013 Aug;19(8):447-53.

Madar S, Harel E, Goldstein I, Stein Y, Kogan-Sakin I, Kamer I, Solomon H, Dekel E, Tal P, Goldfinger N, Friedlander G, Rotter V. Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta. PLoS One. 2013 Apr 22;8(4).

Goldstein I, Yizhak K, Madar S, Goldfinger N, Ruppin E, Rotter V. p53 promotes the expression of gluconeogenesis-related genes and enhances hepatic glucose production. Cancer & Metabolism. 2013 Feb 4;1(1):9.

Goldstein I*, Rivlin N*, Shoshana O, Ezra O, Madar S, Goldfinger N, Rotter V. Chemotherapeutic agents activate p53 to induce the transcription of CYP3A genes in the liver – a novel feedback loop for systemic chemotherapy clearance. Carcinogenesis. 2013 Jan;34(1):190-8.


Goldstein I, Rotter V. Regulation of lipid metabolism by p53 – fighting two villains with one sword. Trends Endocrinol. Metab. 2012 Nov;23(11):567-75. 

Kalo E, Kogan-Sakin I, Solomon H, Bar-Nathan E, Shay M, Shetzer Y, Dekel E, Goldfinger N, Buganim Y, Stambolsky P, Goldstein I, Madar S, Rotter V. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high ROS levels. J Cell Sci. 2012 Nov 15;125(Pt 22):5578-86.

Solomon H, Buganim Y, Pomeraniec L, Beatus T, Assia Y, Kogan-Sakin I, Madar S, Goldstein I, Brosh R, Kalo E, Goldfinger N, Rotter V. Various p53 mutant types differently regulate the Ras circuit to induce a cancer-related gene signature. J Cell Sci. 2012 Jul 1;125(Pt 13):3144-52.

Goldstein I*, Madar S*, Rotter V. Cancer research, a field on the verge of paradigm shift? Trends Mol. Med., 2012 Jun;18(6):299-303. 

Goldstein I, Ezra O, Rivlin N, Molchadsky A, Madar S, Goldfinger N, Rotter V. p53, a novel regulator of lipid metabolism pathways. J Hepatol. Mar;56(3):656-62. 2012. 


Buganim Y, Madar S, Rais Y, Pomeraniec L, Harel E, Solomon H, Kalo E, Goldstein I, Brosh R, Haimov O, Avivi C, Polak-Charcon S, Goldfinger N, Barshack I, Rotter V. Transcriptional activity of ATF3 in the stromal compartment of tumors promotes cancer progression. Carcinogenesis. 2011 Dec;32(12):1749-57.

Madar S*, Goldstein I*, Rotter V. Beyond tumor suppression: p53 controls blastocyst implantation. Cell Cycle. 2011 Dec 15;10(24):4203. 

Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, Goldfinger N, Loewenthal RC, Gazit E, Rotter V, Berger R. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One. 2011 6(7):e21650.

Bornstein C, Brosh R, Molchadsky A, Madar S, Kogan-Sakin I, Goldstein I, Chakravarti D, Flores ER, Goldfinger N, Sarig R, Rotter V. SPATA18, a spermatogenesis-associated gene, is a novel transcriptional target of p53 and p63. Mol Cell Biol. 2011 Apr;31(8):1679-89.

Goldstein I*, Marcel V*, Olivier M, Oren M, Rotter V, Hainaut P. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther. 2011 Jan;18(1):2-11. 


Buganim Y, Solomon H, Rais Y, Kistner D, Nachmany I, Brait M, Madar S, Goldstein I, Kalo E, Adam N, Gordin M, Rivlin N, Kogan I, Brosh R, Sefadia-Elad G, Goldfinger N, Sidransky D, Kloog Y, Rotter V. p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. Cancer Res. 2010 Mar 15;70(6):2274-84.

Buganim Y*, Goldstein I*, Lipson D, Milyavsky M, Polak-Charcon S, Mardoukh C, Solomon H, Kalo E, Madar S, Brosh R, Perelman M, Navon R, Goldfinger N, Barshack I, Yakhini Z, Rotter V. A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype. PLoS One. 2010 Mar 11;5(3):e9657.


Daniel-Carmi V, Makovitzki-Avraham E, Reuven EM, Goldstein I, Zilkha N, Rotter V, Tzehoval E, Eisenbach L. The human 1-8D gene (IFITM2) is a novel p53 independent pro-apoptotic gene. Int J Cancer. 2009 Dec 15;125(12):2810-9.

Goldstein I, Rotter V. Mutations in the tetramerization domain of p53: more than just keeping monomers apart. Cell Cycle. 2009 Oct 15;8(20):3259-60.

S, Goldstein I*, Rotter V. Did experimental biology die? Lessons from 30 years of p53 research. Cancer Res. 2009 Aug 15;69(16):6378-80.

Madar S, Brosh R, Buganim Y, Ezra O, Goldstein I, Solomon H, Kogan I, Goldfinger N, Klocker H, Rotter V. Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis. 2009 Jan;30(1):20-7.


Brosh R, Shalgi R, Liran A, Landan G, Korotayev K, Nguyen GH, Enerly E, Johnsen H, Buganim Y, Solomon H, Goldstein I, Madar S, Goldfinger N, Børresen-Dale AL, Ginsberg D, Harris CC, Pilpel Y, Oren M, Rotter V. p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol. 2008;4:229.

© Designed by HandMed